Aberrant SRC activation plays a role in mediating chemoresistance in PDAC, while therapeutic inhibition of SRC restores chemo-sensitivity of human pancreatic cancer cells [128–130]. The gene discussed is SRC; the disease is pancreatic neoplasm.